Uroplasty To Participate In The Piper Jaffray Healthcare Conference
MINNEAPOLIS, Nov. 21, 2013 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 3:30pm ET and meet with investors one on one at the conference in New York City.
Attendance at the conference is by invitation only. The presentation will be conducted in a fireside chat format and an audio webcast will be broadcast via the Internet. Those interested in joining the webcast may access it through Uroplasty’s website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days following the event.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Brett Reynolds, SVP and CFO
Jenifer Kirtland (Investors)/Janine McCargo (Business Media)
SOURCE Uroplasty, Inc.